Claims
- 1. A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof: ##STR171## wherein symbols represent: A: hydrogen or a phenyl group;
- n: an integer of 4 to 7;
- R.sub.1 : hydrogen atom;
- X.sub.1 : a group shown by --CH.sub.2 --Y.sub.1 -- (wherein Y.sub.1 : --S--), --CO--Y.sub.2 -- (wherein Y.sub.2 : --NH-- or --CH.sub.2 --Y.sub.1);
- B: a group represented by: ##STR172## X.sub.2 : a group represented by --CH.dbd.CH-- or --Y.sub.3 --Y.sub.4 --, wherein Y.sub.3 : a single bond, --O-- or --S--; Y.sub.4 : an alkylene group having 1 to 6 carbon atoms which may be intervened by a sulfur atom.
- D: a carboxy group, or a group represented by: ##STR173##
- 2. A compound as claimed in claim 1, wherein A represents a hydrogen atom or a phenyl group, n is an integer of 4 to 7, R.sub.1 is a hydrogen atom, X.sub.1 is --CO--Y.sub.2 -- (wherein Y.sub.2 is --NH--), B is ##STR174## X.sub.2 is --CH.dbd.CH-- or --Y.sub.3 --Y.sub.4 -- (wherein Y.sub.3 represents a single bond, --O-- or --S--, and Y.sub.4 is an alkylene group having 1 to 6 carbon atoms which may be interrupted by a sulfur atom) and D is a carboxy group or ##STR175##
- 3. A compound as claimed in claim 1, which is [[5-(p-heptyloxybenzamido)-1,3,4-thiadiazol-2-yl]thio]acetic acid.
- 4. A compound as claimed in claim 1, which is [[5-[m-(4-phenylbutoxy)benzamido]-1,3,4-thiadiazol-2-yl]thio]acetic acid.
- 5. A compound as claimed in claim 1, which is 4-[[5-[(p-heptyloxyphenacyl)thio]-1,3,4-thiadiazol-2-yl]thio]butyric acid.
- 6. A pharmaceutical composition useful for inhibiting the production and release of SRS-A comprised of a pharmaceutically acceptable amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
- 7. A pharmaceutical composition useful for inhibiting the production and release of SRS-A comprised of a pharmaceutically acceptable amount of the compound of claim 2 and a pharmaceutically acceptable carrier.
- 8. The pharmaceutical composition of claim 6, wherein said compound is ethyl [[5-(m-heptyloxybenzamido)-1,3,4-thiadiazol-2-yl]thio]acetate.
- 9. The pharmaceutical composition of claim 6, wherein said compound is 4-[[5-[(p-heptyloxyphenacyl)thio-1,3,4-thiadiazol-2-yl]thio]butyrate.
- 10. The pharmaceutical composition of claim 6, wherein said compound is ethyl [[5-(m-(4-phenylbutoxy)benzamido]-1,3-4-thiadiazol-2-yl]thio]acetate.
- 11. The pharmaceutical composition of claim 6, wherein said compound is [[5-(p-heptyloxybenzamido)-1,3,4-thiadiazol-2-yl]thio]acetic acid.
- 12. The pharmaceutical composition of claim 6, wherein said compound is [[5-[m](4-phenylbutoxy)benzamido]-1,3,4-thiadiazol-2-yl]thio]acetic acid.
- 13. The pharmaceutical composition of claim 6, wherein said compound is 4-[[5-[(p-heptyloxyphenacyl)thio]-1,3,4-thiadiazol-2-yl]thio]butyric acid.
- 14. A method for inhibiting the production and release of SRS-A in a subject, which comprises administering to said subject an effective amount for inhibiting the production and release of SRS-A of the pharmaceutical composition of claim 6.
- 15. A method for inhibiting the production and release of SRS-A in a subject, which comprises administering to said subject an effective amount for inhibiting the production and release of SRS-A of the pharmaceutical composition of claim 7.
- 16. The method of claim 14, wherein the compound of the pharmaceutical composition is ethyl [[5-(m-heptyloxybenzamido)-1,3,4-thiadiazol-2-yl]thio]acetate.
- 17. The method of claim 14, wherein the compound of the pharmaceutical composition is 4-[[5-[(p-heptyloxyphenacyl)thio]-1,3,4-thiadiazol-2-yl]thio]-butyrate.
- 18. The method of claim 14, wherein the compound of the pharmaceutical composition is ethyl [[5-(m-(4-phenylbutoxy)benzamido]-1,3,4-thiadiazol-2-yl]thio]acetate.
- 19. The method of claim 14, wherein the compound of the pharmaceutical composition is [[5-(p-heptyloxybenzamido)-1,3,4-thiadiazol-2-yl]thio]acetic acid.
- 20. The method of claim 14, wherein the compound of the pharmaceutical composition is [[5-[m-(4-phenylbutoxy)benzamido]-1,3,4-thiadiazol-2-yl]thio]acetic acid.
- 21. The method of claim 14, wherein the compound of the pharmaceutical composition is 4-[[5-[(p-heptyloxyphenacyl)thio]-1,3,4-thiadiazol-2-yl]thio]butyric acid.
Priority Claims (2)
Number |
Date |
Country |
Kind |
60-70566 |
Apr 1985 |
JPX |
|
60-297096 |
Dec 1985 |
JPX |
|
Parent Case Info
This is a division of application Ser. No. 899,218, filed Aug. 15, 1986, now U.S. Pat. No. 4,994,479.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4803211 |
Mase |
Feb 1989 |
|
Non-Patent Literature Citations (1)
Entry |
Shams-El-Dine, J. Drug. Research 6 203 (1974). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
899218 |
Aug 1986 |
|